Erythromycin Stearate

CHEMBL1200510 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1018.4 g/mol
LogP
Phase
4

The stearate salt of erythromycin, this oral antibiotic is absorbed in the intestine and converted to active erythromycin to treat bacterial infections. The stearate form helps mask the bitter taste of erythromycin in tablet formulations.

分子量

1018.4000 g/mol

TPSA

231.00 Ų

治療領域

作用機序

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

InChI=1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1

Molecular Formula

C55H103NO15

HBD / HBA

6 / 16

回転可能結合数

23

重原子数

71

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The stearate salt of erythromycin, this oral antibiotic is absorbed in the intestine and converted to active erythromycin to treat bacterial infections. The stearate form helps mask the bitter taste of erythromycin in tablet formulations.

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

Yes, Erythromycin Stearate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200510. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 12559. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.